Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Fanny Delehaye - , Université de Caen (Autor:in)
  • Jérémie Rouger - , Université de Caen (Autor:in)
  • David Brossier - , Université de Caen (Autor:in)
  • Meinolf Suttorp - , Klinik und Poliklinik für Kinder- und Jugendmedizin (Autor:in)
  • Adalet Meral Güneş - , Uludag University (Autor:in)
  • Petr Sedlacek - , Karlsuniversität Prag (Autor:in)
  • Birgitta Versluys - , Princess Máxima Center for Pediatric Oncology (Autor:in)
  • Chi Kong Li - , Chinese University of Hong Kong (Autor:in)
  • Krzysztof Kalwak - , Wrocław Medical University (Autor:in)
  • Birgitte Lausen - , Universität Kopenhagen (Autor:in)
  • Culic Srdjana - , Klinički Bolnički Centar (KBC) Split (Autor:in)
  • Michael Dworzak - , St. Anna Kinderkrebsforschungsinstitut, Medizinische Universität Wien (Autor:in)
  • Andrea Hraskova - , University Children's Hospital Bratislava (Autor:in)
  • Barbara De Moerloose - , Ghent University (Autor:in)
  • Farah Roula - , Saint George Hospital University Medical Center (Autor:in)
  • Anaïs Briant - , Université de Caen (Autor:in)
  • Jean Jacques Parienti - , Université de Caen (Autor:in)
  • Frédéric Millot - , CHU de Poitiers (Autor:in)

Abstract

The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its prevalence and its impact on prognosis are not well known. In the International Registry of Childhood CML, we selected children and adolescents in chronic phase at diagnosis of CML and treated upfront with imatinib. We examined their hemoglobin level at diagnosis according to the WHO grades to assess the prevalence of anemia and its impact on response to tyrosine kinase inhibitors (TKIs). Data on 430 patients were included. Anemia at diagnosis was observed in 350 patients (81%), with a mean hemoglobin level of 96.4 g/l (SD 23.6). Among them, 182 patients (52%) presented with moderate anemia and 110 (31%) with severe anemia while 58 (17%) had mild anemia. Compared with mild and no anemia, moderate and severe forms were significantly associated with younger age at diagnosis, asthenia, splenomegaly, and increased leukocyte and basophil counts. Delays in achieving major and deep molecular responses were significantly increased for patients with moderate and severe anemia, and also failure of imatinib treatment was more frequent in these two sub-cohorts. However, hemoglobin level was not significantly associated with survival. Anemia at diagnosis of pediatric CML was frequent and may be considered as a prognostic factor.

Details

OriginalspracheEnglisch
Seiten (von - bis)563-570
Seitenumfang8
FachzeitschriftAnnals of hematology
Jahrgang102
Ausgabenummer3
PublikationsstatusVeröffentlicht - März 2023
Peer-Review-StatusJa

Externe IDs

PubMed 36370190

Schlagworte

ASJC Scopus Sachgebiete

Schlagwörter

  • Anemia, Children, Chronic myeloid leukemia, Leukemia, Pediatric, Prognosis, Prevalence, Humans, Antineoplastic Agents/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Imatinib Mesylate/therapeutic use, Adolescent, Protein Kinase Inhibitors/therapeutic use, Adult, Anemia/drug therapy, Child, Hemoglobins

Bibliotheksschlagworte